Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MHLW

- PMLiVE

FDA knocks back Xarelto once again in ACS

Major setback for Bayer and Johnson & Johnson's oral anticoagulant

- PMLiVE

Bayer fails to overturn Nexavar compulsory licence in India

Natco Pharma allowed to sell cut-price version of cancer drug

- PMLiVE

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of €5.5bn by 2015

- PMLiVE

Second approval in US for Bayer-Onyx’ Stivarga

FDA clears drug to treat patients with gastrointestinal stromal tumours

Product updates from Japan

New approvals and filings include drugs from Takeda, Otsuka, Chugai and Astellas

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

- PMLiVE

Bayer submits oral PAH drug riociguat for approval

Set to challenge Actelion and Gilead

EU flag

Pharma backs new European drug discovery platform

Supporters for the European Lead Factory include Bayer AstraZeneca, Merck KGaA and Sanofi

- PMLiVE

Bayer’s Diane 35 faces ban in France

Follows investigation into blood clot-related deaths

- PMLiVE

EMA starts contraceptive safety probe

Follows French investigation into Bayer’s Diane 35

- PMLiVE

France investigates Bayer’s acne drug Diane 35 after deaths

Linked to blood clots in women

- PMLiVE

Early 2013 sees drug filings, launches and approvals in Japan

Includes medicines from Bayer, Takeda, Astellas and Eisai

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links